05-JUL-2022 6:11

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY ADMIN CCADMIN ACCR.
GOAL		 R
E
G		 O
P
E
N		 ARM TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac PREV   491 0 Y 0 Pre-Registration 692 50 32 4 1 0
              692 50 32 4 1 0
 
        1 Y 1 Blinded drug 131 9 3 1 0 0
            2 Blinded drug 36 0 0 0 0 0
            3 Blinded drug 35 0 0 0 0 0
            4 Blinded drug 137 14 10 6 3 0
              339 23 13 7 3 0
 
S1007-Breast,Adj,N1,Endocrine+/-Chemo BREAST CCD 9400 3 Y 4 Specimen Submission for CBALR TM Substudy 161 161 55 19 3 1
              161 161 55 19 3 1
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol SURV   817 1 Y 0 Screening 292 27 15 9 3 0
              292 27 15 9 3 0
 
        2 Y 1 Carvedilol 57 11 6 3 1 1
            2 No prophylaxis 61 11 7 5 1 0
            3 Observation 155 3 0 0 0 0
              273 25 13 8 2 1
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition SXQOL   200 1 Y 1 Blinded Nutrition Drink 67 27 9 0 0 0
            2 Blinded Nutrition Drink 73 32 9 3 0 0
              140 59 18 3 0 0
 
S1614-HBV in Ca Pts, anti-HBV therapy vs SOC SXQOL   444 1 Y 3 Past, On-Demand anti-HBV 2 2 1 1 0 0
            4 Past, SOC HBV Treatment 2 0 0 0 0 0
              4 2 1 1 0 0
 
S1703-Met Breast, STM-monitoring v Usual Care CCD SXQOL 1320 1 Y 0 Screening 341 81 38 18 7 2
              341 81 38 18 7 2
 
        2 Y 1 Control (Usual Care) 116 34 13 10 3 0
            2 Intervention (STMDDM) 112 29 15 4 0 0
              228 63 28 14 3 0
 
S1706-Breast, Inflammatory, RT +/- Olaparib BREAST SXQOL 300 1 Y 1 Olaparib + RT 48 8 3 1 0 0
            2 RT 56 13 4 3 0 0
              104 21 7 4 0 0
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum GU SXQOL 1273 1 Y 0 Induction SST 565 174 68 24 6 1
              565 174 68 24 6 1
 
        2 Y 1 Standard Systemic Therapy Only 199 70 29 10 2 1
            2 SST + Surgery/RT 205 73 31 12 6 1
              404 143 60 22 8 2
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab GU SXQOL 475 1 Y 0 Initial Registration 314 125 60 30 11 2
              314 125 60 30 11 2
 
        2 Y 1 Chemo + RT 146 58 32 13 6 1
            2 Chemo + RT + Atezolizumab 148 63 28 17 4 0
              294 121 60 30 10 1
 
S1823-GCT, Obs. Cohort, miRNA371 PREV   956 1 Y 1 Observation 528 315 139 52 13 1
              528 315 139 52 13 1
 
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD LYMPH SXQOL 987 1 Y 1 Nivolumab + AVD 445 197 110 49 16 2
            2 Brentuximab Vedotin + AVD 449 202 113 49 17 2
              894 399 223 98 33 4
 
S1827-SCLC, MRI Surveillance +/- PCI LUNG SXQOL 668 1 Y 1 PCI + MRI brain surveillance 50 25 15 6 2 0
            2 MRI brain surveillance 52 26 17 9 3 0
              102 51 32 15 5 0
 
S1904-Breast, Decision making for chemoprevention PREV   415 1 Y 1 Standard Education Materials 85 57 33 14 5 1
            2 Support Tools + Standard Education Materials 98 85 43 28 8 1
              183 142 76 42 13 2
 
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship CCD   536 1 Y 1 Financial Navigation 14 14 11 3 1 0
            2 Control 16 16 13 7 1 1
              30 30 24 10 2 1
 
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo LUNG SXQOL 480 1 Y 1 Atezolizumab and SBRT 56 37 19 11 4 1
            2 SBRT 52 34 17 7 2 0
              108 71 36 18 6 1
 
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP LYMPH SXQOL 422 1 Y 1 CC-486 + R-miniCHOP 18 17 8 5 1 0
            2 R-miniCHOP 17 16 8 4 2 0
              35 33 16 9 3 0
 
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O LEUK SXQOL 247 1 Y 1 Delayed V-O 10 8 5 4 1 0
            2 Early V-O 17 14 9 5 1 0
              27 22 14 9 2 0
 
S2013-I-CHECKIT: ICI toxicity risk prediction study SXQOL   2062 1 Y 1 Observation Arm 309 309 251 122 37 7
              309 309 251 122 37 7
 
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib BREAST SXQOL   1 E   10 7 3 1 1 0
              10 7 3 1 1 0
 
A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC GI SXQOL   1 E   59 11 3 3 0 0
              59 11 3 3 0 0
 
A021806-Pancreas, Perioperative vs Adjuvant Chemo GI SXQOL   0 E   19 13 5 2 2 1
              19 13 5 2 2 1
 
        1 E   16 11 3 1 1 0
              16 11 3 1 1 0
 
A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) GU SXQOL   1 E   12 4 1 0 0 0
              12 4 1 0 0 0
 
A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo GU SXQOL   1 E   90 27 12 5 1 0
              90 27 12 5 1 0
 
        2 E   61 24 16 7 2 0
              61 24 16 7 2 0
 
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO LUNG SXQOL   1 E   36 20 5 4 2 0
              36 20 5 4 2 0
 
ACCL16N1-Guideline Consistent Treatment AYA ALL CCD     1 T   54 0 0 0 0 0
              54 0 0 0 0 0
 
EA2186-PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI GI SXQOL   1 E   16 8 2 2 1 0
              16 8 2 2 1 0
 
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) MMYEL SXQOL   0 E   13 10 4 1 0 0
              13 10 4 1 0 0
 
        1 E   7 5 4 1 0 0
              7 5 4 1 0 0
 
        2 E   3 3 3 2 1 0
              3 3 3 2 1 0
 
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT BREAST SXQOL   1 E   9 2 2 2 1 0
              9 2 2 2 1 0
 
        2 E   10 4 2 2 1 0
              10 4 2 2 1 0
 
NRGBR004-BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo BREAST SXQOL   1 E   13 5 3 1 0 0
              13 5 3 1 0 0
 
        2 E   9 4 2 0 0 0
              9 4 2 0 0 0
 
NRGCC003-SCLC, PCI or HA-PCI LUNG SXQOL   1 E   5 1 0 0 0 0
              5 1 0 0 0 0
 
        2 E   5 1 0 0 0 0
              5 1 0 0 0 0
 
NRGGU005-PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT GU SXQOL   1 E   9 3 0 0 0 0
              9 3 0 0 0 0
 
NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST LUNG SXQOL   1 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo GI SXQOL   1 E   17 5 1 0 0 0
              17 5 1 0 0 0
 
        2 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
A031801-GU, mRCC, Cabozantinib +/- Radium-223 GU SXQOL   1 E   6 4 2 0 0 0
              6 4 2 0 0 0
 
A031901-Blad, Adv/ Met, Duration of Immune Chkpt Tx GU SXQOL   0 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
A031902-Pros, Adv, Enzalutamide + Rucaparib GU SXQOL   0 E   4 4 1 0 0 0
              4 4 1 0 0 0
 
        1 E   4 4 1 0 0 0
              4 4 1 0 0 0
 
A071801-Brain, Mets, Post-Srg Single SRS vs Fract SRS OTHER SXQOL   0 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
        1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
A191901-Brst, Text/Motivational Intervention ET Adher CCD     1 E   36 34 16 2 0 0
              36 34 16 2 0 0
 
A211102-Breast, Atypia via RPFNA, Metformin v Placebo PREV     0 E   6 0 0 0 0 0
              6 0 0 0 0 0
 
        1 E   3 0 0 0 0 0
              3 0 0 0 0 0
 
        2 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
A221702-BREAST, SLN/ALND +/- ARM SXQOL     1 E   17 2 2 2 1 0
              17 2 2 2 1 0
 
A221805-Colorectal, Duloxetine for Oxaliplatin CIPN SXQOL     1 E   5 2 1 1 0 0
              5 2 1 1 0 0
 
        2 E   6 6 2 2 1 0
              6 6 2 2 1 0
 
A222004-Mult, Olanza vs Megestrol for Anorexia SXQOL     1 E   2 2 2 1 0 0
              2 2 2 1 0 0
 
A231601C-CCD, OPTI-Surg in older cancer patients CCD     1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
A231602C-Blood Cancer, Assess Financial Difficulty CCD     1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
A231701C-Brst, Srg Decision Engagement CCD     1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
A231901C-Breast, Shared Decision Engagement System CCD SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo OTHER SXQOL   1 T   4 3 3 2 0 0
              4 3 3 2 0 0
 
EA2182-Anal, Erly, DECREASE GI SXQOL   0 E   2 2 2 2 1 1
              2 2 2 2 1 1
 
        1 E   2 2 2 2 1 1
              2 2 2 2 1 1
 
EA2185-Panc, Impact of Panc Cyst Surveillance PREV SXQOL   1 E   8 5 3 1 0 0
              8 5 3 1 0 0
 
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL   1 E   8 1 0 0 0 0
              8 1 0 0 0 0
 
EA8183-Pros, Dbl Blind Andro Dep + Daro vs Placebo GU SXQOL   0 E   7 6 3 1 0 0
              7 6 3 1 0 0
 
        1 E   3 2 0 0 0 0
              3 2 0 0 0 0
 
EAA173-MYEL, SMM, Rd +/- Daratumumab MMYEL SXQOL   0 E   37 10 5 1 0 0
              37 10 5 1 0 0
 
        1 E   19 6 3 2 0 0
              19 6 3 2 0 0
 
EAQ171CD-Smoke Free Support Study 2.0 CCD     0 E   3 2 2 2 0 0
              3 2 2 2 0 0
 
        1 E   3 2 2 2 0 0
              3 2 2 2 0 0
 
        2 E   2 2 2 2 0 0
              2 2 2 2 0 0
 
EAQ202-Improving AYA PROs in EA Trials SXQOL SXQOL   1 E   32 32 26 14 3 0
              32 32 26 14 3 0
 
EAZ171-Breast, Stg I-III, TIPN Docetaxel/Paclitaxel SXQOL     1 E   3 0 0 0 0 0
              3 0 0 0 0 0
 
G0263-Cerv, Stg I/IIA, adjv RT vs chemoRT OTHER SXQOL   1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
NHLBIMDS-LEUK, National MDS Study CCD     1 E   166 46 19 9 3 1
              166 46 19 9 3 1
 
NRGBN003-Mening, Grd II, Observation vs Irradiation OTHER SXQOL   1 E   5 0 0 0 0 0
              5 0 0 0 0 0
 
        2 E   3 0 0 0 0 0
              3 0 0 0 0 0
 
NRGBN007-Brain, New Dx, Ipi + Nivo vs Temozomide OTHER SXQOL   1 E   8 6 2 2 0 0
              8 6 2 2 0 0
 
        2 E   5 5 1 1 0 0
              5 5 1 1 0 0
 
NRGBR007-Breast, Stg I, De-Escalation of Breast RT BREAST SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
        2 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
NRGCC007-CCD, Increased Dose of SCP in Pros Survivors CCD     0 E   23 8 1 1 0 0
              23 8 1 1 0 0
 
        1 E   23 8 1 1 0 0
              23 8 1 1 0 0
 
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO PREV SXQOL   1 E   2 1 1 0 0 0
              2 1 1 0 0 0
 
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy GI SXQOL   1 Y   15 1 0 0 0 0
              15 1 0 0 0 0
 
NRGGU009-Pros, PREDICT-RT GU SXQOL   1 E   4 4 4 3 2 0
              4 4 4 3 2 0
 
        2 E   3 3 3 2 2 0
              3 3 3 2 2 0
 
NRGGU010-Pros, Parallel De-Intens & Intens Trials GU SXQOL   1 E   3 3 1 0 0 0
              3 3 1 0 0 0
 
        2 E   3 3 3 0 0 0
              3 3 3 0 0 0
 
NRGGY005-OVAR, Cedir vs Olaparib vs C+O vs Std of Care OTHER SXQOL   1 E   4 0 0 0 0 0
              4 0 0 0 0 0
 
NRGGY018-Endo, Stg III-IVB/Recur, Pac/Carbo +/- Pembro OTHER SXQOL   1 E   10 8 4 3 2 1
              10 8 4 3 2 1
 
        2 E   4 4 1 0 0 0
              4 4 1 0 0 0
 
NRGGY020-Endo, Erly Stg, Rando RT +/- Pembro OTHER SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
NRGHN001-Nasopharyngeal , Indiviual Tx EBV OTHER SXQOL   1 E   9 0 0 0 0 0
              9 0 0 0 0 0
 
        2 E   8 0 0 0 0 0
              8 0 0 0 0 0
 
        3 E   7 0 0 0 0 0
              7 0 0 0 0 0
 
NRGHN004-HN, Adv, RT+Durvalumab vs RT+Cetuximab OTHER SXQOL   1 E   6 0 0 0 0 0
              6 0 0 0 0 0
 
        2 E   6 0 0 0 0 0
              6 0 0 0 0 0
 
NRGHN005-HN, early stg P16-pos, randomize de-intensifi OTHER SXQOL   1 E   6 2 0 0 0 0
              6 2 0 0 0 0
 
NRGHN006-HN, Erly Stg, Biopsy vs Dissection OTHER SXQOL   2 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN OTHER SXQOL   1 E   2 2 2 1 0 0
              2 2 2 1 0 0
 
NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo LUNG SXQOL   1 E   14 8 5 0 0 0
              14 8 5 0 0 0
 
R0724-Cervical, Chem+RT +/- Adj. Chemo OTHER SXQOL   1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux OTHER SXQOL   1 E   5 1 0 0 0 0
              5 1 0 0 0 0
 
        2 E   4 1 0 0 0 0
              4 1 0 0 0 0
 
R1308-Lung, Stg II/III, Photon vs Proton Chemo RT LUNG SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0